Franklin India Technology Fund-Growth vs WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
Side-by-side comparison of NAV, returns, expense ratio and star rating.
TopFund Analysis
Franklin India Technology Fund-Growth appears stronger due to its higher star rating of 5 compared to WhiteOak Capital Pharma and Healthcare Fund Direct Plan Growth's rating of 4, indicating a better overall assessment. However, investors should note that Franklin India Technology Fund has a higher expense ratio of 1.16% versus 1.06% for WhiteOak Capital, which could impact net returns. For those considering sector-specific investments, Franklin India offers more stability in terms of historical performance, while WhiteOak Capital shows impressive recent returns but lacks long-term data. Ultimately, investors should weigh the higher rating and historical performance of Franklin India against the lower expense ratio of WhiteOak Capital.
Franklin India Technology Fund-Growth
Franklin Templeton Mutual Fund
★★★★★
Equity · Sectoral
WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
WhiteOak Capital Mutual Fund
★★★★★
Equity · Sectoral
| Metric | Franklin India Technol... | WhiteOak Capital Pharm... |
|---|---|---|
| NAV | ₹544.36 | ₹17.8 |
| Star Rating | ★★★★★ | ★★★★ |
| Expense Ratio | 1.16% | 1.06% |
| AUM | ₹1,742 Cr | ₹1,002 Cr |
| 1M Return | +5.45% | +4.29% |
| 3M Return | -0.29% | +2.5% |
| 6M Return | +13.03% | +17.96% |
| 1Y Return | -5.8% | +20.62% |
| 3Y CAGR | +10.29% | — |
| 5Y CAGR | +7.22% | — |
| Risk Level | — | — |
| Fund Manager | Anand Radhakrishnan, Srikesh Nair, Varun Sharma | Ashish Agrawal |